L0521

Lipoxin A₄

ethanol solution

• 동의어(들): (5S,6R,15S)-Trihydroxy-(7E,9E,11Z,13E)-Eicosatetraenoic acid
• 실험식(Hill 표기법): C₂₀H₃₂O₅
• CAS Number: 89663-86-5
• Molecular Weight: 352.47
• EC Number: 200-578-6
• MDL number: MFCD00065845
• UNSPSC 코드: 12352211
• PubChem Substance ID: 24896257
• NACRES: NA.77

속성

• 양식: ethanol solution
• Quality Level: 200
• 배송 상태: dry ice
• 저장 온도: −20°C
• SMILES string: CCCCC[C@H](O)\C=C\C=C/C=C/C=C/[C@@H](O)[C@@H](O)CCCC(O)=O
• InChI: 1S/C20H32O5/c1-2-3-8-12-17(21)13-9-6-4-5-7-10-14-18(22)19(23)15-11-16-20(24)25/h4-7,9-10,13-14,17-19,21-23H,2-3,8,11-12,15-16H2,1H3,(H,24,25)/b6-4-,7-5+,13-9+,14-10+/t17-,18+,19-/m0/s1
• InChI key: IXAQOQZEOGMIQS-SSQFXEBMSA-N

설명

생화학적/생리학적 작용

Lipoxin A4 (LXA4) is synthesized from arachidonic acid and is an endogenous lipoxygenase-derived eicosanoid mediator. It is a potent human protein kinase C activator. It inhibits cytotoxicity of natural killer cells. LXA4 regulates the immune system and inflammation. In the brain, it modulates neuronal signaling and slow wave sleep. LXA4 binds to cannabinoid receptors. LXA4 plays a key role in the maintenance of endometrium and reproductive function. Depletion of LXA4 contributes to the pathophysiology of cystic fibrosis (CF).

포장

Packaged under argon.

안전성 정보

• 픽토그램: GHS02,GHS07
• 신호어: Danger
• 유해 및 위험 성명서: H225,H319
• 예방조치 성명서: P210 - P233 - P240 - P241 - P242 - P305 + P351 + P338
• Hazard Classifications: Eye Irrit. 2 - Flam. Liq. 2
• Storage Class Code: 3 - Flammable liquids
• WGK: WGK 2
• Flash Point (°F): 55.4 °F
• Flash Point (°C): 13 °C
• 개인 보호 장비: Eyeshields, Faceshields, Gloves, type ABEK (EN14387) respirator filter